Senseonics Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Senseonics Holdings is Tim Goodnow, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.59M, bestaande uit 17.1% salaris en 82.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.84% van de aandelen van het bedrijf, ter waarde € 1.51M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 8.2 jaar.

Belangrijke informatie

Tim Goodnow

Algemeen directeur

US$3.6m

Totale compensatie

Percentage CEO-salaris	17.1%
Dienstverband CEO	8.9yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tim Goodnow's beloning veranderd ten opzichte van Senseonics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$80m
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$4m	US$613k	-US$60m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	US$57m
Dec 31 2022	US$4m	US$586k	US$142m
Sep 30 2022	n/a	n/a	US$215m
Jun 30 2022	n/a	n/a	US$318m
Mar 31 2022	n/a	n/a	US$34m
Dec 31 2021	US$3m	US$569k	-US$302m
Sep 30 2021	n/a	n/a	-US$489m
Jun 30 2021	n/a	n/a	-US$555m
Mar 31 2021	n/a	n/a	-US$382m
Dec 31 2020	US$3m	US$552k	-US$175m
Sep 30 2020	n/a	n/a	-US$109m
Jun 30 2020	n/a	n/a	-US$105m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$2m	US$536k	-US$116m
Sep 30 2019	n/a	n/a	-US$87m
Jun 30 2019	n/a	n/a	-US$100m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$2m	US$536k	-US$94m
Sep 30 2018	n/a	n/a	-US$103m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$520k	-US$59m

Compensatie versus markt: De totale vergoeding ($USD 3.59M ) Tim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 808.68K ).

Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tim Goodnow (62 yo)

8.9yrs

Tenure

US$3,589,760

Compensatie

Dr. Timothy T. Goodnow, also known as Tim, Ph D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% € 1.5m
Mukul Jain	Chief Operating Officer	7.8yrs	US$1.56m	0.32% € 580.8k
Kenneth Horton	General Counsel & Corporate Development Advisor	7.1yrs	US$1.31m	0.21% € 373.4k
Francine Kaufman	Chief Medical Officer & Director	5.7yrs	geen gegevens	0.19% € 341.9k
Frederick Sullivan	CFO, Secretary & Treasurer	2.2yrs	geen gegevens	0.092% € 165.5k

7.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6L6 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% € 1.5m
Francine Kaufman	Chief Medical Officer & Director	5yrs	geen gegevens	0.19% € 341.9k
Douglas Roeder	Independent Non-Management Director	8.9yrs	US$174.75k	0.15% € 262.5k
Edward Fiorentino	Independent Non-Management Director	8.9yrs	US$169.00k	0.16% € 282.5k
Stephen DeFalco	Independent Chairman	8.9yrs	US$210.00k	0.29% € 516.5k
Steven Edelman	Independent Non-Management Director	8.2yrs	US$164.00k	0.14% € 259.4k
Douglas Prince	Independent Non-Management Director	8.9yrs	US$182.50k	0.12% € 213.7k
Brian Hansen	Director	less than a year	geen gegevens	geen gegevens
Anthony Raab	Independent Non-Management Director	4.1yrs	US$152.50k	0.080% € 143.2k
Sharon Larkin	Independent Non-Management Director	2.9yrs	US$159.00k	0.046% € 82.7k
Koichiro Sato	Director	1.5yrs	geen gegevens	geen gegevens

8.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6L6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Senseonics Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Independent Non-Management Director recently bought €148k worth of stock

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Senseonics Holdings, Inc. Announces CFO Transition

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

President recently sold €1.0m worth of stock

Recent updates

New minor risk - Shareholder dilution

Senseonics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $16 million.

Senseonics Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Mercy Places First Commercial Eversense 365

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.033 loss per share (vs US$0.036 loss in 2Q 2023)

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.031 loss per share (vs US$0.003 profit in 1Q 2023)

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.30 profit in FY 2022)

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought €148k worth of stock

New minor risk - Profitability

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.036 loss per share (vs US$0.23 profit in 2Q 2022)

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

First quarter 2023 earnings released: EPS: US$0.003 (vs US$0.19 in 1Q 2022)

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$0.30 (vs US$0.72 loss in FY 2021)

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.096 profit in 3Q 2021)

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$0.23 (vs US$0.42 loss in 2Q 2021)

Investor sentiment improved over the past week

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings released: EPS: US$0.19 (vs US$0.69 loss in 1Q 2021)

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

President recently sold €1.0m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director recently sold €389k worth of stock

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020)

Senseonics Holdings, Inc Announces the Results of the Promise Study Evaluating the Accuracy and Safety of the Next Generation Eversense CGM System for Up to 180 Days with Reduced Calibrations

Independent Non-Management Director Peter Klein has left the company

Senseonics Holdings, Inc. Reports Impairment Costs for the First Quarter Ended March 31, 2021

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.21 loss in 1Q 2020)

Senseonics Holdings, Inc. Provides Revenue Guidance for the Full Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$0.72 loss per share (vs US$0.61 loss in FY 2019)

Senseonics Holdings, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €2.53

Senseonics Holdings, Inc. Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth

New 90-day high: €1.44

Senseonics Holdings, Inc. announced that it has received $60.8 million in funding from Masters Special Situations, LLC, PHC Holdings Corporation, Masters Capital Management, L.L.C.

New 90-day high: €0.76

Senseonics Holdings, Inc. Increases Financial Guidance for the Fourth Quarter 2020

New 90-day high: €0.38